File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy

TitleElevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy
Authors
KeywordsChemotherapy
Soluble interleukin-2 receptor
Tuberculosis
Issue Date1995
PublisherEuropean Respiratory Society. The Journal's web site is located at http://erj.ersjournals.com
Citation
European Respiratory Journal, 1995, v. 8 n. 1, p. 70-73 How to Cite?
AbstractSoluble interleukin-2 receptor (sIL-2R) is a marker of T-lymphocyte activation. We have undertaken a study to examine the serum sIL-2R levels in patients with pulmonary tuberculosis (TB) and the changes following anti-TB chemotherapy. Forty four patients with pulmonary TB or tuberculous pleural effusion were recruited. Serum was collected from the patients before and at 1, 2, 4 and 6 months after initiation of anti-TB chemotherapy. Serum sIL-2R level was measured by an enzyme immunoassay. The mean sIL-2R level before treatment was 1,452±103 (SEM) U·ml-1, which was significantly higher than that of healthy control subjects (374±30 U·ml-1). There was no significant change in the sIL-2R level at 1 month, but there was a gradual reduction from the second month onwards. At the sixth month the mean sIL-2R level was 1080±81 U·ml-1, which was significantly lower than that before treatment. However, despite clinical improvement, the sIL,2R levels at the sixth month were still significantly higher than those of control subjects. We conclude that sIL-2R levels were elevated in patients with pulmonary TB and there was a gradual reduction following anti-TB chemotherapy. However, the sIL-2R levels were still higher than control subjects at completion of treatment, suggesting a delayed resolution of the inflammation in patients with pulmonary TB.
Persistent Identifierhttp://hdl.handle.net/10722/162063
ISSN
2015 Impact Factor: 8.332
2015 SCImago Journal Rankings: 3.204
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, CHSen_HK
dc.contributor.authorLai, CKWen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorHo, ASSen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2012-09-05T05:17:00Z-
dc.date.available2012-09-05T05:17:00Z-
dc.date.issued1995en_HK
dc.identifier.citationEuropean Respiratory Journal, 1995, v. 8 n. 1, p. 70-73en_HK
dc.identifier.issn0903-1936en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162063-
dc.description.abstractSoluble interleukin-2 receptor (sIL-2R) is a marker of T-lymphocyte activation. We have undertaken a study to examine the serum sIL-2R levels in patients with pulmonary tuberculosis (TB) and the changes following anti-TB chemotherapy. Forty four patients with pulmonary TB or tuberculous pleural effusion were recruited. Serum was collected from the patients before and at 1, 2, 4 and 6 months after initiation of anti-TB chemotherapy. Serum sIL-2R level was measured by an enzyme immunoassay. The mean sIL-2R level before treatment was 1,452±103 (SEM) U·ml-1, which was significantly higher than that of healthy control subjects (374±30 U·ml-1). There was no significant change in the sIL-2R level at 1 month, but there was a gradual reduction from the second month onwards. At the sixth month the mean sIL-2R level was 1080±81 U·ml-1, which was significantly lower than that before treatment. However, despite clinical improvement, the sIL,2R levels at the sixth month were still significantly higher than those of control subjects. We conclude that sIL-2R levels were elevated in patients with pulmonary TB and there was a gradual reduction following anti-TB chemotherapy. However, the sIL-2R levels were still higher than control subjects at completion of treatment, suggesting a delayed resolution of the inflammation in patients with pulmonary TB.en_HK
dc.languageengen_US
dc.publisherEuropean Respiratory Society. The Journal's web site is located at http://erj.ersjournals.comen_HK
dc.relation.ispartofEuropean Respiratory Journalen_HK
dc.subjectChemotherapyen_HK
dc.subjectSoluble interleukin-2 receptoren_HK
dc.subjectTuberculosisen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshEmpyema, Tuberculous - Drug Therapy - Immunologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshReceptors, Interleukin-2 - Analysisen_US
dc.subject.meshTuberculosis, Pulmonary - Drug Therapy - Immunologyen_US
dc.titleElevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapyen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1183/09031936.95.08010070en_HK
dc.identifier.pmid7744196-
dc.identifier.scopuseid_2-s2.0-0028798868en_HK
dc.identifier.volume8en_HK
dc.identifier.issue1en_HK
dc.identifier.spage70en_HK
dc.identifier.epage73en_HK
dc.identifier.isiWOS:A1995QJ69900012-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridChan, CHS=16169208100en_HK
dc.identifier.scopusauthoridLai, CKW=7403086390en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridHo, ASS=7402675199en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats